Tempus AI Stock Soars 108% in 2025 Amid Mixed Q4 Earnings and Future Prospects
8 Sources
[1]
Tempus AI Stock Has Soared 108% Already in 2025; Is It a Buy Now? | The Motley Fool
Only time will tell if the market enthusiasm that drove artificial intelligence (AI) stocks higher in 2024 will extend through 2025. But one ticker that may be less recognizable among the AI crowd is certainly off to a roaring start since the ball fell on New Year's Eve. Skyrocketing 108% since
[2]
Tempus AI Earnings: Growth Is Here, But So Are The Risks (NASDAQ:TEM)
Looking for a helping hand in the market? Members of Deep Value Returns get exclusive ideas and guidance to navigate any climate. Learn More " Investment Thesis Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main
[3]
Tempus AI Stock Gears Up For Q4 Earnings After 101% YTD Surge - Tempus AI (NASDAQ:TEM)
Tempus AI Inc TEM will be reporting its fourth-quarter earnings on Monday. Wall Street expects a loss of 20 cents per share and $203.12 million in revenues as the company reports after market hours. The stock is up over 70% over the past year, 101% YTD. Let's look at what the charts indicate for
[4]
Tempus AI Costs, Outlook Send Stock Sharply Lower
Tempus AI gave weaker-than-expected guidance for full-year adjusted EBITDA. Shares of Tempus AI (TEM) sank 17% Tuesday, a day after the provider of artificial intelligence medical technology reported worse-than-anticipated results and guidance, with costs rising as the company expanded. Tempus
[5]
Tempus AI Q4 Earnings: Revenue Miss, EPS Beat, Strong Guidance, Shares Move Lower - Tempus AI (NASDAQ:TEM)
Tempus AI Inc TEM reported fourth-quarter financial results after the market close on Monday. Here's a look at the key metrics from the quarter. Q4 Earnings: Tempus AI reported fourth-quarter revenue of $200.68 million, missing estimates of $203.12 million. The AI-focused precision medicine and
[6]
What's Going On With Tempus AI Shares Monday? - Tempus AI (NASDAQ:TEM)
Tempus AI, Inc. TEM shares are moving higher on Monday. The company may be moving higher ahead of its 2024 fiscal-year fourth-quarter earnings report, which is scheduled to be released after the market closes. What To Know: Analysts estimate a loss per share of 20 cents and revenue of $203.12
[7]
Tempus AI Stock Is Tumbling Tuesday: What's Happening? - Tempus AI (NASDAQ:TEM)
Tempus AI Inc TEM shares are trading lower Tuesday after the company reported mixed fourth-quarter financial results. JPMorgan also downgraded the stock following the print. Q4 Revenue: $200.68 million, versus estimates of $203.12 million Q4 EPS: Loss of 18 cents, versus estimates for a loss of 20
[8]
The Analyst Verdict: Tempus AI In The Eyes Of 7 Experts - Tempus AI (NASDAQ:TEM)
Tempus AI TEM underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding
Share
Copy Link
Tempus AI, an AI-driven healthcare company, sees its stock price surge 108% in 2025 despite mixed Q4 earnings. The company's future looks promising but faces challenges in profitability and market expectations.
Tempus AI's Remarkable Stock Performance
Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen its stock soar by an impressive 108% since the start of 2025
1
. This surge comes despite a mixed fourth-quarter earnings report for 2024, which saw the company's shares drop by approximately 17% following the announcement4
. The stock's performance has caught the attention of investors, particularly after Cathie Wood's Ark Invest took a bullish stance on the company in mid-January1
.Q4 2024 Earnings and Financial Performance
Tempus AI reported fourth-quarter revenue of $200.68 million, falling short of the estimated $203.12 million
5
. However, the company beat earnings expectations with an adjusted loss of 18 cents per share, compared to the anticipated loss of 20 cents per share5
. Key highlights from the earnings report include:- Total revenue up 35.8% year-over-year
- Data and services revenue grew 44.6% to $80.2 million
- Genomics revenue increased 30.6% to $120.4 million
- Net revenue retention rate of 140%
- Cash and equivalents of approximately $340.95 million at quarter-end
5
Future Outlook and Guidance
Despite the mixed Q4 results, Tempus AI provided strong guidance for 2025:
- Expected full-year 2025 revenue of approximately $1.24 billion, representing 79% annual growth
- Anticipated full-year 2025 adjusted EBITDA of $5 million, compared to a loss of $104.7 million in 2024
5
CEO Eric Lefkofsky expressed confidence in the company's AI investments, stating they have positioned Tempus AI well for the future
5
.Investor Sentiment and Market Reaction
The stock's recent performance has been influenced by several factors:
- Ark Invest's bullish stance and increased position in Tempus AI
1
- Collaboration announcement with the Institute for Follicular Lymphoma Innovation
1
- Former House Speaker Nancy Pelosi's disclosure of call option purchases
5
However, the stock faces some challenges, including:
- Short-term bearish pressure evident in technical analysis
3
- Concerns about the company's path to profitability
1
- Mixed analyst ratings with an average price target implying potential downside
3
Related Stories
Key Metrics to Watch
Investors should keep an eye on several important metrics:
- Growth in the genomics business, particularly oncology NGS tests delivered
1
- Net revenue retention rate, which stood at 125% in 2023
1
- Progress towards achieving positive adjusted EBITDA in 2025
1
- The company's ability to manage operating expenses while expanding
4
Conclusion
Tempus AI's stock performance in 2025 has been remarkable, but the company faces both opportunities and challenges ahead. While its AI-driven healthcare solutions show promise, the path to profitability and meeting market expectations will be crucial for sustained investor confidence.
References
Summarized by
Navi
[4]
Related Stories
Tempus AI Reports Strong Q2 2025 Results, Driven by AI-Powered Genomics and Data Services
08 Aug 2025•Business and Economy
Tempus AI Rebounds with New AI-Driven Healthcare Initiatives Amid Short Seller Allegations
03 Jun 2025•Technology
Tempus AI Stock Soars on Collaboration with Follicular Lymphoma Institute, Attracts Major Institutional Investors
14 Feb 2025•Technology
Recent Highlights
1
AI Hallucination Nearly Sparked US Military Confrontation With Chinese Ship in Middle East
Technology
2
OpenAI AI Agent Hacks Australian Government Healthcare Website in First-of-Its-Kind Breach
Technology
3
AI leaders warn UN Security Council of existential risks to humanity, call for global safeguards
Policy and Regulation
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
